References
- Tanda ML, Piantanida E, Liparulo L, et al. Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed graves’ hyperthyroidism seen at a single center. Clin Endocrinol Metab. 2013;98:1443–1449. doi:10.1210/jc.2012-3873
- Perros P, Hegedüs L, Bartalena L, et al. Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement. Orphanet J Rare Dis. 2017;12:72. doi:10.1186/s13023-017-0625-1
- Mourits MP, Prummel MF, Wiersinga WM, Koorneef L. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf). 1997;47:9–14. doi:10.1046/j.1365-2265.1997.2331047.x
- Gorman CA. The measurement of change in Graves’ ophthalmopathy. Thyroid. 1998;8:539–543. doi:10.1089/thy.1998.8.539
- Terwee CB, Gerding MN, Dekker FW, Prummel MF, Wiersinga WM. Development of a disease specific quality of life questionnaire for patients with Graves’ ophthalmopathy: the GO-QOL. Br J Ophthalmol. 1998;82:773–779. doi:10.1136/bjo.82.7.773
- Le Moli R, Pluchino A, Muscia V, et al. Graves’ orbitopathy: extraocular muscle/total orbit area ratio is positively related to the Clinical Activity Score. Eur J Ophthalmol. 2012;22:301–308.
- Wiersinga WM, Regensburg NI, Mourits MP. Differential involvement of orbital fat and extraocular muscles in Graves’ ophthalmopathy. Eur Thyroid J. 2013;2:14–21. doi:10.1159/000348246
- Łacheta D, Miśkiewicz P, Głuszko A, et al. Immunological aspects of Graves’ ophthalmopathy. Biomed Res. 2019. doi:10.1155/2019/7453260
- Smith TJ, Koumas L, Gagnon A, et al. Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2002;87:385–392. doi:10.1210/jcem.87.1.8164
- Olejarz M, Parulska ES, Dadej D, Gutaj SN, Domin R, Ruchała M. IgG4 as a biomarker in Graves’ orbitopathy. Mediators Inflamm. 2021;2021:1–11. doi:10.1155/2021/5590471
- Bahn SR. Graves’ ophthalmopathy. N Engl J Med. 2010;362:726–738. doi:10.1056/NEJMra0905750
- Chan LL, Tan HE, Fook-Chong S, Teo TH, Lim LH, Seah LL. Graves ophthalmopathy: the bony orbit in optic neuropathy, its apical angular capacity, and impact on prediction of risk. Am J Neuroradiol. 2009;30:597–602. doi:10.3174/ajnr.A1413
- Khong J, McNab A, Ebeling P, Craig J, Selva D. Pathogenesis of thyroid eye disease: review and update on molecular mechanisms. Br Ophthalmol. 2016;100:142–150. doi:10.1136/bjophthalmol-2015-307399
- Zhao R, Jiang S, Zhang L, Bin Yu Z. Mitochondrial electron transport chain, ROS generation and uncoupling (Review). Int J Mol Med. 2019;44:3–15. doi:10.3892/ijmm.2019.4188
- Cawood TJ, Moriarty P, O’Farrelly C, O’Shea D. Smoking and thyroid-associated ophthalmopathy: a novel explanation of the biological link. J Clin Endocrinol Metab. 2007;92:59–64. doi:10.1210/jc.2006-1824
- Sabini E, Mazzi B, Profilo MA, et al. High serum cholesterol is a novel risk factor for Graves’ orbitopathy (GO): results of a cross- sectional study. Thyroid. 2017. doi:10.1089/thy.2017.0430
- Naselli A, Moretti D, Regalbuto C, et al. Evidence that baseline levels of low-density lipoproteins cholesterol affect the clinical response of Graves’ ophthalmopathy to parenteral corticosteroids. Front Endocrinol. 2020;11. doi:10.3389/fendo.2020.609895
- Yu G, Tzouvelekis A, Wang R, et al. Thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function. Nat Med. 2018;24:39–49. doi:10.1038/nm.4447
- Dave TV, Jonnadula GB, Lanka P, Natarajan R, Dave VP. Choroidal vascularity index in thyroid eye disease: comparison with controls and application in diagnosing non-inflammatory active disease. Orbit. 2022;41:89–96. doi:10.1080/01676830.2021.2014893
- Dave TV, Natarajan R, Reddy RU, Kapoor AG, Dave VP. Choroidal thickness in thyroid eye disease: comparison with controls and application in diagnosing non-inflammatory active disease. Cureus. 2021;13(11):e19779. doi:10.7759/cureus.19779